Electromed (NASDAQ: ELMD) logs 15th straight growth quarter as CEO eyes 2027 exit
Rhea-AI Filing Summary
Electromed, Inc. (ELMD) reported record results for the fourth quarter and fiscal year ended June 30, 2026, and announced a planned CEO transition. Fiscal 2026 net revenues increased 15.3% to $73.8 million, led by direct homecare revenue up 16.3% to $66.6 million. Gross profit rose to $57.9 million with a gross margin of 78.5%. Operating income grew to $13.9 million, or 18.8% of net revenues, compared to 15.1% in fiscal 2025. Net income was $11.3 million, or $1.30 per diluted share, up from $7.5 million or $0.85.
For Q4 2026, net revenues increased 11.6% to $19.4 million, with net income of $3.4 million and diluted EPS of $0.39. The company highlighted its 15th consecutive quarter of year-over-year revenue and profit growth and homecare revenue per sales representative of $1,145,000, above its $1,000,000–$1,100,000 target range. As of June 30, 2026, Electromed had $20.5 million in cash, no debt, working capital of $45.1 million, and shareholders’ equity of $54.0 million.
Electromed also disclosed that President and CEO Jim Cunniff notified the company of his intention to retire on or about April 2, 2027, and is expected to resign from the Board at that time. The Board has engaged an executive search firm and begun a comprehensive search for the next CEO.
Positive
- Fiscal 2026 net revenues grew 15.3% to $73.8 million, with direct homecare revenue up 16.3% to $66.6 million, demonstrating sustained double-digit top-line growth.
- Operating leverage improved as operating income increased to $13.9 million, or 18.8% of net revenues, compared with 15.1% in fiscal 2025.
- Net income rose to $11.3 million, or $1.30 diluted EPS, up from $7.5 million and $0.85, respectively, reflecting strong profitability gains.
- The balance sheet strengthened, with $20.5 million in cash, no debt, working capital of $45.1 million, and shareholders’ equity of $54.0 million.
- Electromed generated $9.7 million of operating cash flow in fiscal 2026 while repurchasing $3.9 million of common stock, indicating capacity to return capital.
- The company achieved its 15th consecutive quarter of year-over-year revenue and profit growth, highlighting consistent operating performance.
Negative
- President and CEO Jim Cunniff plans to retire on or about April 2, 2027 and is expected to resign from the Board, introducing leadership transition risk despite an ongoing executive search.
Filing Explained
The filing adds that Electromed repurchased
8-K Event Classification
Key Figures
Key Terms
High Frequency Chest Wall Oscillation medical
Bronchiectasis medical
working capital financial
forward-looking statements regulatory
SmartVest® Airway Clearance System medical
Offering Details
FAQ
How did Electromed (ELMD) perform financially in fiscal 2026?
What were Electromed’s Q4 2026 results?
What is Electromed’s current balance sheet position?
What leadership changes did Electromed announce?
How is Electromed’s core homecare business performing?
What margins does Electromed (ELMD) achieve compared to peers?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification
Number)
|
|
|
|
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
||
|
(Title of each class)
|
(Trading Symbol)
|
(Name of each exchange on which registered)
|
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press Release (Earnings Announcement) dated August 25, 2026
|
|
|
99.2
|
Company Investor Presentation dated August 25, 2026
|
|
|
99.3
|
Press Release (Executive Succession) dated August 25, 2026
|
|
|
104
|
Cover Page Interactive Data File (embedded in the cover page and formatted in inline XBRL)
|
|
|
ELECTROMED, INC.
|
|
|
|
|
|
|
|
|
Date: August 25, 2026
|
By: /s/ Bradley M. Nagel
|
|
|
|
|
Name:
|
Bradley M. Nagel
|
|
|
|
Title:
|
Chief Financial Officer
|
|
Exhibit 99.1
Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
Strong homecare revenue growth and expanded operating leverage drive record operating income in Fiscal 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ("Q4 FY 2026") and full year ended June 30, 2026 ("FY 2026").
Q4 FY 2026 Company Highlights
|
● |
Net revenue increased 11.6% to a record $19.4 million in Q4 FY 2026, from $17.4 million in the fourth quarter of the prior fiscal year. |
|
● |
Operating income increased 25.8% over the prior year to a record $3.8 million, or 19.7% of net revenues. |
|
● |
Net income increased 54.3% to a record $3.4 million, or $0.39 per diluted share, compared to $2.2 million, or $0.25 per diluted share, in the fourth quarter of the prior fiscal year. |
FY 2026 Company Highlights
|
● |
Net revenue increased 15.3% to a record $73.8 million in FY 2026, from $64.0 million in the prior fiscal year. |
|
● |
Operating income increased 43.7% over the prior year to a record $13.9 million, or 18.8% of net revenues. |
|
● |
Net income was $11.3 million, or $1.30 per diluted share, compared to $7.5 million, or $0.85 per diluted share, in the prior fiscal year. |
|
● |
Cash provided by operations totaled $9.7 million in FY 2026, compared to $11.4 million in the prior fiscal year. |
|
● |
Electromed repurchased $3.9 million of its common stock throughout FY 2026. |
“Fiscal 2026 was another exceptional year for Electromed, as the company generated record revenues and profits. The fourth fiscal quarter marked our 15th consecutive quarter of year-over-year revenue and profit growth. Also, our operating margin increased more than 370 basis points over FY 2025, which demonstrates our continued success in driving operational leverage. Our strong financial performance, combined with strategic investments in our sales force, systems, and bronchiectasis market development initiatives, positions us to capitalize on the opportunity to serve the approximately 800,000 diagnosed bronchiectasis patients who could benefit from our SmartVest® therapy. Our robust balance sheet with $20.5 million in cash, and recognition as one of Minnesota’s fastest-growing public companies has Electromed well-positioned for durable, long-term growth and value creation for our investors.”
Q4 FY 2026 Results
All amounts below are for the three months ended June 30, 2026, and compare to the three months ended June 30, 2025.
Net revenues grew 11.6% to $19.4 million from $17.4 million.
Revenue in our direct homecare business increased 15.2% to $17.7 million from $15.4 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval.
Gross profit increased to $15.3 million or 78.7% of net revenues from $13.6 million or 78.3% of net revenues. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.
Selling, general and administrative (“SG&A”) expenses were $11.1 million, representing an increase of $0.8 million or 8.3%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process higher patient referrals.
Operating income was $3.8 million or 19.7% of net revenues, compared to $3.0 million, or 17.5% of net revenues. This increase in operating income was primarily due to increases in revenue and gross profit.
Net income increased by 54.3% to $3.4 million, or $0.39 per diluted share, compared to $2.2 million, or $0.25 per diluted share.
FY 2026 Summary
All amounts below are for the year ended June 30, 2026 ("fiscal 2026") and compare to the fiscal year ended June 30, 2025 ("fiscal 2025").
Net revenues for fiscal 2026 grew by 15.3% to a record $73.8 million, from $64.0 million in fiscal 2025.
Revenue in our direct homecare market increased year-over-year by 16.3% to $66.6 million, from $57.3 million. The increase in revenue was due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per approval. For the year ended June 30, 2026, we averaged 58 homecare field sales representatives. The homecare revenue per weighted average direct sales representative was $1,145,000, exceeding Electromed's target range for the year of $1,000,000 to $1,100,000.
Revenue in our non-homecare business grew to $7.2 million in fiscal 2026, an increase of $0.5 million, or 6.7%, from $6.7 million in fiscal 2025. The increase was primarily due to increased distributor and hospital revenue.
Gross profit increased to $57.9 million, or 78.5% of net revenues in fiscal 2026, from $50.0 million, or 78.1% of net revenues, in fiscal 2025. The increase in gross profit and gross margin was primarily due to increased revenue and higher net revenue per device.
Selling, general and administrative (“SG&A”) expenses were $42.7 million in fiscal 2026, representing an increase of $3.4 million or 8.7% from $39.3 million in fiscal 2025. The increase was primarily due to increased salaries and incentive compensation related to the higher average number of personnel in the sales, sales support, marketing, and reimbursement teams to process more patient referrals.
Operating income was $13.9 million or 18.8% of net revenues in fiscal 2026, compared to $9.7 million, or 15.1% of net revenues in fiscal 2025. This increase in operating income was primarily due to increases in net revenues and gross profit.
Net income for fiscal 2026 was $11.3 million, or $1.30 per diluted share, compared to $7.5 million, or $0.85 per diluted share in fiscal 2025.
As of June 30, 2026, Electromed had $20.5 million in cash, $29.8 million in accounts receivable and no debt, achieving working capital of $45.1 million and total shareholders’ equity of $54.0 million. The cash balance reflects an increase of $5.2 million for the twelve months ended June 30, 2026, compared to a decrease in cash of $0.8 million in the twelve months ended June 30, 2025. The increase in cash for the twelve months ended June 30, 2026, was driven primarily by positive operating cash flow of $9.7 million, partially offset by share repurchases of $3.9 million of Electromed common stock.
Conference Call and Webcast Information
The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, August 25, 2026.
Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).
The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1770216&tp_key=c0342b57c3
For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 13761827. Additionally, an online replay will be available for at least one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Cautionary Statements
Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “continue,” “expect,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown, associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641
mike.cavanaugh@icrhealthcare.com
Source: Electromed, Inc.
Electromed, Inc.
Condensed Balance Sheets
|
As of June 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Assets |
||||||||
|
Current Assets |
||||||||
|
Cash and cash equivalents |
$ | 20,450,000 | $ | 15,287,000 | ||||
|
Accounts receivable (net of allowances for credit losses of $45,000) |
29,805,000 | 24,660,000 | ||||||
|
Contract assets |
1,094,000 | 1,036,000 | ||||||
|
Inventories |
3,681,000 | 3,299,000 | ||||||
|
Prepaid expenses and other current assets |
1,170,000 | 392,000 | ||||||
|
Income tax receivable |
1,168,000 | 408,000 | ||||||
|
Total current assets |
57,368,000 | 45,082,000 | ||||||
|
Property and equipment, net |
5,214,000 | 4,714,000 | ||||||
|
Finite-life intangible assets, net |
379,000 | 371,000 | ||||||
|
Other assets |
1,270,000 | 1,173,000 | ||||||
|
Deferred income taxes |
2,036,000 | 2,462,000 | ||||||
|
Total assets |
$ | 66,267,000 | $ | 53,802,000 | ||||
|
Liabilities and Shareholders’ Equity |
||||||||
|
Current Liabilities |
||||||||
|
Accounts payable |
$ | 2,643,000 | $ | 2,667,000 | ||||
|
Accrued compensation |
6,071,000 | 5,079,000 | ||||||
|
Warranty reserve |
1,899,000 | 1,645,000 | ||||||
|
Other accrued liabilities |
1,609,000 | 1,077,000 | ||||||
|
Total current liabilities |
12,222,000 | 10,468,000 | ||||||
|
Other long-term liabilities |
66,000 | 125,000 | ||||||
|
Total liabilities |
12,288,000 | 10,593,000 | ||||||
|
Shareholders’ Equity |
||||||||
|
Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,366,163 and 8,349,176 shares issued and outstanding, as of June 30, 2026, and June 30, 2025, respectively |
84,000 | 83,000 | ||||||
|
Additional paid-in capital |
25,331,000 | 21,941,000 | ||||||
|
Retained earnings |
28,564,000 | 21,185,000 | ||||||
|
Total shareholders’ equity |
53,979,000 | 43,209,000 | ||||||
|
Total liabilities and shareholders’ equity |
$ | 66,267,000 | $ | 53,802,000 | ||||
Electromed, Inc.
Condensed Statements of Operations
|
Three Months Ended |
Year Ended |
|||||||||||||||
|
June 30, |
June 30, |
|||||||||||||||
|
2026 |
2025 |
2026 |
2025 |
|||||||||||||
|
(Unaudited) |
(Unaudited) |
|||||||||||||||
|
Net revenues |
$ | 19,417,000 | $ | 17,393,000 | $ | 73,776,000 | $ | 64,000,000 | ||||||||
|
Cost of revenues |
4,133,000 | 3,769,000 | 15,833,000 | 14,029,000 | ||||||||||||
|
Gross profit |
15,284,000 | 13,624,000 | 57,943,000 | 49,971,000 | ||||||||||||
|
Operating expenses |
||||||||||||||||
|
Selling, general and administrative |
11,131,000 | 10,282,000 | 42,748,000 | 39,315,000 | ||||||||||||
|
Research and development |
328,000 | 302,000 | 1,314,000 | 996,000 | ||||||||||||
|
Total operating expenses |
11,459,000 | 10,584,000 | 44,062,000 | 40,311,000 | ||||||||||||
|
Operating income |
3,825,000 | 3,040,000 | 13,881,000 | 9,660,000 | ||||||||||||
|
Interest income, net |
136,000 | 135,000 | 479,000 | 624,000 | ||||||||||||
|
Net income before income taxes |
3,961,000 | 3,175,000 | 14,360,000 | 10,284,000 | ||||||||||||
|
Income tax expense |
560,000 | 971,000 | 3,059,000 | 2,747,000 | ||||||||||||
|
Net income |
$ | 3,401,000 | $ | 2,204,000 | $ | 11,301,000 | $ | 7,537,000 | ||||||||
|
Income per share: |
||||||||||||||||
|
Basic |
$ | 0.41 | $ | 0.26 | $ | 1.37 | $ | 0.89 | ||||||||
|
Diluted |
$ | 0.39 | $ | 0.25 | $ | 1.30 | $ | 0.85 | ||||||||
|
Weighted-average common shares outstanding: |
||||||||||||||||
|
Basic |
8,258,440 | 8,334,821 | 8,266,071 | 8,454,100 | ||||||||||||
|
Diluted |
8,734,188 | 8,718,900 | 8,688,563 | 8,914,421 | ||||||||||||
Electromed, Inc.
Condensed Statements of Cash Flows
|
Years Ended June 30, |
||||||||
|
2026 |
2025 |
|||||||
|
Cash Flows from Operating Activities |
||||||||
|
Net income |
$ | 11,301,000 | $ | 7,537,000 | ||||
|
Adjustments to reconcile net income to net cash provided by operating activities: |
||||||||
|
Depreciation |
868,000 | 1,039,000 | ||||||
|
Impairment of intangible assets |
— | 212,000 | ||||||
|
Amortization |
208,000 | 133,000 | ||||||
|
Share-based compensation expense |
2,722,000 | 3,059,000 | ||||||
|
Deferred income taxes |
426,000 | (310,000 | ) | |||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
(5,145,000 | ) | (1,327,000 | ) | ||||
|
Contract assets |
(58,000 | ) | (317,000 | ) | ||||
|
Inventories |
(517,000 | ) | 175,000 | |||||
|
Prepaid expenses and other assets |
(1,024,000 | ) | (959,000 | ) | ||||
|
Income tax receivable, net |
(760,000 | ) | (685,000 | ) | ||||
|
Accounts payable and accrued liabilities |
652,000 | 1,650,000 | ||||||
|
Accrued compensation |
992,000 | 1,186,000 | ||||||
|
Net cash provided by operating activities |
9,665,000 | 11,393,000 | ||||||
|
Cash Flows from Investing Activities |
||||||||
|
Expenditures for property and equipment |
(1,252,000 | ) | (262,000 | ) | ||||
|
Expenditures for finite-life intangible assets |
(48,000 | ) | (44,000 | ) | ||||
|
Net cash used for investing activities |
(1,300,000 | ) | (306,000 | ) | ||||
|
Cash Flows from Financing Activities |
||||||||
|
Issuance of common stock upon exercise of options |
965,000 | 398,000 | ||||||
|
Taxes paid on net share settlement of stock awards |
(249,000 | ) | (2,278,000 | ) | ||||
|
Repurchase of common stock |
(3,918,000 | ) | (10,000,000 | ) | ||||
|
Net cash used for financing activities |
(3,202,000 | ) | (11,880,000 | ) | ||||
|
Net increase (decrease) in cash |
5,163,000 | (793,000 | ) | |||||
|
Cash and cash equivalents |
||||||||
|
Beginning of period |
15,287,000 | 16,080,000 | ||||||
|
End of period |
$ | 20,450,000 | $ | 15,287,000 | ||||
Exhibit 99.2
Electromed, Inc. Investor Presentation August 25, 2026 NYSE American: ELMD Innovation Leader in Airway Clearance Technologies
Slide 2: Forward looking statements - Certain statements in this presentation constitute forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “believe,” “committed,” “continue,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Slide 3: Electromed – Who We Are - Electromed, Inc. is a growing medical device company focused on airway management to help people around the world breathe better, stay healthier, and lead active and fulfilling lives. Key Stats: Headquarters: New Prague, MN Ticker: ELMD Manufacturing: Minnesota, USA Established: 1992 Treatment Focus: HFCWO Employees: 197* LTM Net Revenues: $73.8M* Market Cap: $350M* Cash / Debt: $20.5M / $0.0M* *As of and for the 12 months ended 06/30/2026
Electromed Highlights ● Growing and profitable medical technology company ● A leader in the large and expanding airway clearance market ● The SmartVest® Airway Clearance System’s High Frequency Chest Wall Oscillation (“HFCWO”) technology supported by clinical outcomes data with strong reimbursement. ● Attractive direct-to-patient and provider model ● Strong financial profile with attractive gross margins and well-capitalized balance sheet 35% Operating Income CAGR* *FY ‘21 through FY26 FY21: Operating Income: $3.1M Revenue: $35.8M FY22: Operating Income: $3.0M Revenue: $41.7M FY23: Operating Income: $4.0M Revenue: $48.1M FY24: Operating Income: $6.5M Revenue: $54.7M FY25: Operating Income: $9.7M Revenue: $64.0M FY26: Operating Income: $13.9M Revenue: $73.8M
What is Bronchiectasis (BE)? BE is a condition that is prevalent, but underdiagnosed and often misdiagnosed ● Irreversible, chronic lung condition where airways become abnormally widened ● Caused by impaired ability to clear mucus, which leads to recurrent inflammation and infections ● Mean prevalence of Bronchiectasis in patients with COPD is 54%¹ 1.Chalmers J. and Sethi S. Raising awareness of Bronchiectasis in primary care: overview of diagnosis and management strategies in adults. NPJ Prim Care Respir Med. 2017;27:18. Disease Misdiagnosed – Disease Underdiagnosed – HFCWO Under-prescribed Normal airways, lungs in cross-section, widened airways – normal airway – airway wall – muscle Airway with bronchiectasis – widened airway, mucus, scarred and thickened airway wall
U.S. Market: Large, Growing, Underpenetrated The Company is expanding awareness within the large BE patient population ~166K HFCWO Adopted - Estimated HFCWO Bronchiectasis penetration, treated population1 Bronchiectasis HFCWO penetration ~16%1 ~$3.1B - Estimated Revenue Opportunity for HFCWO Within Primary Pulmonology Callpoint2 ((1 million – 166K) x 35% x $10.5K) = $3.1B2 ~1 million U.S. BE Diagnosed - Estimated Net Bronchiectasis Prevalence, Diagnosed3 Diagnosed BE population has grown at ~12% annually3 4.1 Million U.S. Undiagnosed - Potential Total Addressable Market - $15.1B (4.1M x $10.5K) - Estimated Bronchiectasis Prevalence, Undiagnosed With COPD / BE Overlap4 35% of BE patients managed by pulmonologists3 1. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database, GUIDEHOUSE 2023 literature review and 2024 S2N HFCWO Claims data. 2. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 35% of BE patients managed by pulmonologists and $10.5K represents the assumed HFCWO ASP. 3. Internal company estimates derived from GUIDEHOUSE 2023 NASM claims database. 4. Internal company estimates derived from GUIDEHOUSE 2023 literature review and 2023 CDC NHANES data.
How is Bronchiectasis Treated? HFCWO therapy mimics manual Chest Percussion Therapy (CPT) 1. Clear Airways FirstTM With SmartVest® 2. Treat The Infection (Antibiotics) 3. Reduce The Inflammation (Anti-Inflammatories) On average, HFCWO therapy is performed as follows: 2x per day, 15 minutes per session, 7 days a week How does SmartVest® HFCWO therapy work? Air-pulse technology – a generator delivers repeating pulses of air through a single hose to an inflated wearable vest. Gentle squeeze and release – each pulse gently squeezes and releases the chest to thin and loosen mucus in the lungs. Airway clearance – mucus is propelled upward toward major airways where it can be coughed and more easily. Airway clearance – smartvest – reduce inflammation – treat infection – complete bronchiectasis care
SmartVest ® Clearway HFCWO designed with the patient in mind SmartVest® has a well-established reimbursement code from CMS – E0483; the Company estimates it has over 275 million contracted lives in the U.S. An Enhanced Patient Experience - Sleek and lightweight generator - Intuitive user interface for better patient adherence - More portable and easier for travel
SmartNotes™ Patient Progress Report - Tracking patient outcomes and treatment progress to physicians SmartNotes combines patient Quality of Life and Therapy Utilization data to provide physicians with extended views into disease management ● Proactive, ongoing support: Licensed Respiratory Therapists stay connected with patients and support their therapy utilization ● Outcomes Management: Easy-to-read report provides physicians with a comprehensive view of therapy impact
Clinical Evidence & Patient Satisfaction - HFCWO therapy is effective in treating BE patients “Therapy with SmartVest® significantly decreased exacerbations requiring hospitalization, antibiotic use, and stabilizes lung function” - Powner 94% Of patients would recommend the SmartVest® to others3 97% Of patients report feeling better or the same after SmartVest® use3 99% Of patients report an increase in sputum production3 57% Reduction in antibiotic prescriptions1 59% Decrease in hospitalizations1 75% Fewer emergency department visits2 1. Sievert CE, et al 2016. Using High Frequency Chest Wall Oscillation in a Bronchiectasis Patient Population: An Outcomes-Based Case Review. Respiratory Therapy, 11(4), 34-38. 2. Sievert CE, et al 2018. Incidence of Bronchiectasis-Related Exacerbation Rates After HFCWO Treatment—A Longitudinal Outcome-Based Study, Respiratory Therapy, 13(2), 38-41. 3. Patient data on file. “Therapy with HFCWO demonstrated key health outcomes improved in post- compared to pre-index period: cough, all-cause hospitalizations, pneumonia, and pulmonary hospitalizations” - DeKoven
Direct-to-Patient Model - Drives an attractive margin profile Electromed expects 78% gross margins to continue improving going forward Traditional Medical Equipment Channel: Manufacturer > Home Medical Equipment (HME) Distributor > Patient Direct-to-Patient Distribution (Electromed): Electromed > Patient
Net Revenue Breakdown - $73.8M (FY’26) By Setting: 94% Home Care (Includes $3.3 million from home care distributor revenue), 5% Hospitals, 1% Other Homecare by Payer: 50% Commercial/Other (Includes Managed Medicare and Managed Medicaid), 48% Medicare, 2% Medicaid Homecare Qualified Referral Volume: 76% Bronchiectasis, 19% Neuromuscular, 3% Cystic Fibrosis, 2% Other
Electromed Growth Strategy - Leveraging commercial team and reimbursement expertise to accelerate growth Electromed, Inc: ● Protect and grow homecare core o Protect and grow Homecare core with current strategy (sales force expansion, payor contracting, market development) as well as converting low prescribers to high prescribers and target high BE diagnosing physicians who are not prescribing SmartVest® ● Expand into natural adjacencies o Leverage existing technology platform – Pediatrics and Hospital (leveraging DTC and GPO contracts) ● Acquisition opportunities o Explore potential inorganic acquisition opportunities
Capital Allocation Strategy: Proven execution against the Company’s priorities Capital Allocation: Organic Business Growth > Generate Free Cash Flow > Potential Strategic Investments or Return to Shareholders FY2026 Execution: ● New Technology & CAPEX investments ● Sales rep expansion ● Market development ● Treat SMART from the Start campaign ● Payor coverage expansion $3.9 million of shares repurchased in FY26
Why invest? Large, expanding chronic lung diseases market, clinically proven technology, broad payor coverage, consistent double-digit organic revenue growth, high gross margins, robust cash flow and expanding operating leverage
Performance vs. Russell Medical Equipment Index (TTM and as of 6/30/2026 Results): Sales Growth: ELMD 15.3% > RUS ME 9.8% Gross Margin: ELMD 78.5% > RUS ME 53.9% Operating Margin: ELMD 18.8% > RUS ME (2.4)%
Electromed, Inc.: Jim Cunniff, President & CEO, (952) 758-9299, jcunniff@electromed.com – Brad Nagel, CFO, (952) 758-9299, bnagel@electromed.com ICR Healthcare: Mike Cavanaugh, (617) 877-8641, mike.cavanaugh@icrhealthcare.com
Appendix
Financial Highlights (in $ millions, except share amounts) Year Ended June 30, 2025: Revenues $64.0 Gross Profit $50.0 Gross Margin 78.1% Operating Income $9.7 Operating Margin 15.1% Net Income $7.5 Diluted EPS $0.85 Diluted Shares 8,914,421 Cash Provided by Operations $11.4 Year Ended June 30, 2026: Revenues $73.8 Gross Profit $57.9 Gross Margin 78.5% Operating Income $13.9 Operating Margin 18.8% Net Income $11.3 Diluted EPS $1.30 Diluted Shares 8,688,563 Cash Provided by Operations $9.7
Exhibit 99.3
Electromed Announces CEO’s Planned Retirement
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that Jim Cunniff expects to retire as President and Chief Executive Officer, on or about April 2, 2027. Upon his retirement, he will resign from the Company’s Board of Directors. The Board of Directors intends to conduct a national search for Electromed’s next President and Chief Executive Officer and has engaged an executive search firm to assist in the process.
Mr. Cunniff has served as the Company’s President and Chief Executive Officer and as a member of its Board of Directors since 2023. During his tenure, he has strengthened Electromed’s position as a leader in HFCWO airway clearance technology, has delivered consistent double-digit net revenues growth and significant operating margin expansion, which has led to improved shareholder value.
“It has been an honor to lead Electromed over the last three years. Our company just delivered its 15th consecutive quarter of year-over-year revenue and profit growth, has a talented and successful leadership team, and is well positioned for continued success. I look forward to working with the board and management team over the coming months to identify an exemplary leader for our business and help ensure a successful transition.”
“On behalf of the board, I would like to thank Jim for his positive impact on our business, the patients we serve, and our shareholders during his tenure as CEO and a member of our board,” said Kathleen Skarvan, Chair of the Board of Directors. “The board is committed to selecting a world-class successor, and we are grateful to have his continued leadership and guidance throughout this transition process.”
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Cautionary Statements
Certain statements in this press release, including the timing and outcomes of potential executive transitions, constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “expect,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown, associated with such statements. Examples of risks and uncertainties for the company include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases, inflationary trends in electronic components, and uncertainty related to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; rising energy costs and geopolitical conflict; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in the company’s reports filed with the Securities and Exchange Commission (including the company’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Contacts
Brad Nagel, Chief Financial Officer
(952) 758-9299
investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com